

Webinars

Constitutional thrombocytopenia

EuroBloodNet 

Benefits and limitations of high-throughput sequencing for the diagnosis of constitutional thrombocytopenia

Kathleen Freson

KULeuven

ERN-EuroBloodNet subnetwork Rare bleeding-coagulation disorders and related diseases


Leuven– Belgium

July 3rd 2024




Co-funded by
the Health Programme
of the European Union






Unrestricted research grant from Swedish Orphan Biovitrum (SOBI)



1. Design of an NGS panel test to diagnose inherited thrombocytopenia
2. Diagnostic rate using NGS panel test for inherited thrombocytopenia
3. Pro and Cons of using NGS panel test for inherited thrombocytopenia: using examples from the clinic

Inherited thrombocytopenia : 41 genes



Variants in these genes cause inherited thrombocytopenia

Gene curation to deliver diagnostic-grade genes (TIER1)



RECOMMENDATIONS AND GUIDELINES *J Thromb Haemost.* 2019;17:1253–1260. **jth**

Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH

Karyn Megy^{1,2,3} | Kate Downes^{1,2,3} | Ilenia Simeoni^{1,2,3} | Loredana Bury⁴ |
Joannella Morales⁵ | Rutendo Mapeta^{1,2,3} | Daniel B. Bellissimo⁶ | Paul F. Bray⁷ |
Anne C. Goodeve⁸ | Paolo Gresele⁴ | Michele Lambert^{9,10} | Pieter Reitsma¹¹ |
Willem H. Ouwehand^{1,2,3} | Kathleen Freson¹² | on behalf of the Subcommittee on
Genomics in Thrombosis and Hemostasis

SSC Scientific and
Standardization
Committee

› www.isth.org/page/GinTh_GeneLists

› Yearly updates during the SSC session

ORIGINAL ARTICLE *J Thromb Haemost.* 2024;22:645–665 **jth**

Evaluating the clinical validity of genes related to hemostasis and thrombosis using the Clinical Genome Resource gene curation framework

Justyne E. Ross¹ | Shruthi Mohan¹ | Jing Zhang² | Mia J. Sullivan³ |
Loredana Bury⁴ | Kristy Lee¹ | Isabella Futchi¹ | Annabelle Frantz¹ |
Dara McDougal¹ | Juliana Perez Botero^{3,5} | Marco Cattaneo⁶ | Nichola Cooper⁷ |
Kate Downes⁸ | Paolo Gresele⁴ | Catriona Keenan⁹ | Alfred I. Lee¹⁰ |
Karyn Megy^o | Pierre-Emmanuel Morange^{11,12} | Neil V. Morgan¹³ |
Harald Schulze¹⁴ | Karen Zimowski¹⁵ | Kathleen Freson¹⁶ | Michele P. Lambert^{17,18}



[Get Started](#) • [About Us](#) • [Curation Activities](#) • [Working Groups](#) • [Expert Panels](#) • [Doc](#)

Clinical Domain Working Groups

Hemostasis/Thrombosis Gene Curation Expert Panel


Affiliated to Hemostasis/Thrombosis CDWG

(syndromic) Inherited (macro/micro)thrombocytopenia



<p>Syndromic thrombocytopenia</p>	<p>ABCG5 (AR) ABCG8 (AR) ACTB (AD) CDC42 (AD) DIAPH1 (AD) FLNA (X-linked) GATA1 (X-linked) GNE (AR)</p>	<p>MPIG6B (AR) MYH9 (AD) SRC (AD)</p>	<p>ANKRD26 (AD) ETV6 (AD) FLI1 as part of large deletion (AD) HOXA11 (AD) KDSR (AR) MECOM (AD) RAP1B (AD) RBM8A (AR) RUNX1 (AD)</p>	<p>STIM1 (AD) ERG (AD)</p>	<p>ARPC1B (AR) WAS (X-linked)</p>
	<p>ACTN1 (AD) GFI1B (AD&AR) GP1BA (AD&AR) GP1BB (AD&AR) GP9 (AD&AR) ITGA2B (AD) ITGB3 (AD) NBEAL2 (AR)</p>	<p>SLFN14 (AD) TPM4 (AD) TUBB1 (AD&AR)</p>	<p>CYCS (AD) FLI1 (AD&AR) IKZF5 (AD) MPL (AR) THPO (AD&AR)</p>		<p>FYB1 (AR)</p>
<p>Non-syndromic thrombocytopenia</p>	<p>Large</p>	<p>Normal</p>	<p>Small</p>		

2016: From Single gene analysis to Multi-gene panels




Sanger sequencing, MLPA, CNV

Past

Today

Targeted, Whole Exome Sequencing (WES) or
Whole Genome Sequencing (WGS)



MULTI-GENE PANEL TEST
(Virtual)

Implementation of multi-gene panel test : ThromboGenomics study



[ABOUT US](#) [SUBMISSION PROCESS](#) [GENE AND DISORDER LIST](#) [PEOPLE](#) [EVENTS](#) [CONTACT US](#)


THROMBOGENOMICS

The first comprehensive next generation sequencing test for the diagnosis of inherited bleeding, thrombotic and platelet disorders.

[Find out more](#)

[SUBMIT](#)
[Your samples](#)

[GENE](#)
[Disorders list](#)



Simeoni I, et al. Blood. 2016

ThromboGenomics Version 1




Regular Article

THROMBOSIS AND HEMOSTASIS


Ilania Simeoni, *Blood* 2016

A comprehensive high-throughput sequencing test for the diagnosis of inherited bleeding, thrombotic, and platelet disorders



- ◆ Bleeding, Thrombotic and Platelet Disorder genes
- ◆ Targetted approach with coverage: 99 – 98 %
- ◆ Detection indels (no inversions)
- ◆ Mean of 5.34 variants/case after filtering
- ◆ Multiplexing 24 (later 48) samples

ThromboGenomics Version 2




Regular Article

THROMBOSIS AND HEMOSTASIS


Kate Downes, *Blood* 2019

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders



Diagnostic rate for thrombocytopenia is nearly 50%


Genes involved in patients with IT



NGS panel for bleeding and thrombosis in the clinic



Age index



Christine Van Laer

Interim analysis

<https://doi.org/10.1016/j.jth.2022.12.007>


J Thromb Haemost. 2023;21:887-895

jth

BRIEF REPORT

Clinical application of multigene panel testing for bleeding, thrombotic, and platelet disorders: a 3-year Belgian experience


Christine Van Laer^{1,2} | Marc Jacquemin^{1,2} | Sarissa Baert³ | Veerle Labarque¹ | Chantal Thys¹ | Thomas Vanassche^{1,5} | Chris Van Geet^{1,4} | Peter Verhamme¹ | Karen Willekens³ | Anniek Corveleyn³ | Kathelijne Peerlinck^{1,5} | Kathleen Freson¹



Workflow using multi-gene panel


ACMG		CLASS
	Pathogenic	5
	Likely pathogenic	4
	VOUS	3
	Likely benign	2
	Benign	1

Results genetic testing (2019 –2022)



Platelet genes

● 1. (L)PV ● 2. VUS ● 3. NEG




**European
Reference
Network**
for rare or low prevalence
complex diseases

⚙ Network
Hematological
Diseases (ERN EuroBloodNet)

Genes involved in patients with IPD



● LPV ● PV ● VUS



**European
Reference
Network**
for rare or low prevalence
complex diseases

Network
Hematological
Diseases (ERN EuroBloodNet)

Strengths and Limitations of NGS panel test




Strengths	<ul style="list-style-type: none">Cost and time efficientImproved diagnostic rateImproved gene curation for BPDImproved variant curation using ACMG classification rulesAllows detection of the unexpected (e.g. oligogenic inheritance, exceptional phenotype-genotype relations)
Limitations	<ul style="list-style-type: none">Low diagnostic rate for indistinct phenotypesMany variants are novel (classified as VUS) and require further studiesNeed for improved DNA variant databasesEthical concerns related to leukemia genes and carrier detectionLack of structural variant detection (including F8 intron 22 inversion)

Variant Capture Tool to improve classification



814 Variants have been submitted from 30 diagnostic labs from 14 countries



Variant reclassification by ClinGen working groups for thrombosis & hemostasis

What do I tell the patient about NGS testing?



SSC Scientific and
Standardization
Committee

RECOMMENDATIONS AND GUIDELINES | Open Access |

Clinical management, ethics and informed consent related to multi-gene panel-based high throughput sequencing testing for platelet disorders: Communication from the SSC of the ISTH

Kate Downes, Pascal Borry, Katrin Ericson, Keith Gomez, Andreas Greinacher, Michele Lambert, Eva Leinoe, Patrizia Noris, Chris Van Geet, Kathleen Freson , Subcommittee on Genomics in Thrombosis, Hemostasis ... [See fewer authors](#)

First published: 08 July 2020 | <https://doi.org/10.1111/jth.14993>

Risk for unsolicited findings using a panel test for IT



Unsolicited findings: refer to variants in disease-causing genes that are unrelated to the original rationale for testing and that are identified inadvertently

Examples:

RUNX1, ETV6 and ANKRD26 variants that are risk factors for leukaemia when testing for platelet disorders

Carriership of variants in recessive genes

Risk of unsolicited findings: an example



Index case, 35 y

Mucocutaneous bleeding symptoms

Platelet count 145- 161 K, normal size

Platelet delta storage pool disease

RUNX1 p.Glu5ValfsTer5

BRIEF REPORT | DECEMBER 12, 2013


Enrichment of *FLI1* and *RUNX1* mutations in families with excessive bleeding and platelet dense granule secretion defects

 Brief Report

Jacqueline Stockley, Neil V. Morgan, Danai Bem, Gillian C. Lowe, Marie Lordkipanidzé, Ban Dawood, Michael A. Simpson, Kirsty Macfarlane, Kevin Horner, Vincenzo C. Leo, Katherine Talks, Jayashree Motwani, Jonathan T. Wilde, Peter W. Collins, Michael Makris, Steve P. Watson,
Martina E. Daly on behalf of the UK Genotyping and Phenotyping of Platelets Study Group

 Check for updates

Blood (2013) 122 (25): 4090–4093.



Poll taken @EAHAD meeting 2019



Question 1

I have requested a genetic panel (or exome) test to diagnose patients with thrombocytopenia and did inform my patient that this test contains genes that are known risk factors for leukaemia?

1. YES
2. NO

Outcome : +/- 50 / 50 %


Question 2

Patients should sign an informed consent before participating in a genetic panel (or exome) with the possibility of an opt_in/opt-out choice to know about variants in leukemic risk genes?

1. YES
2. NO

Outcome : +/- 60 / 40 %

Detection of a missed diagnosis



- Index case, 22 y
- Bleeding after trauma, menorrhagia (same for her mother)
- Macrothrombocytopenia (PLT 125K, MPV >13fL)
- Normal aggregations and ATP secretion
- FACS normal CD61, CD41 and 50% for CD42
- Prolonged PFA (171 s – COL/EPI and 136s – COL/ADP)



GP1BB p.Leu16Pro

BRIEF REPORT | JANUARY 26, 2017


Rare variants in *GP1BB* are responsible for autosomal dominant macrothrombocytopenia

Brief Report

Suthesh Sivapalaratnam, Sarah K. Westbury, Jonathan C. Stephens, Daniel Greene, Kate Downes, Anne M. Kelly, Claire Lentaigne, William J. Astle, Eric G. Huizinga, Paquita Nurden, Sofia Papadia, Kathelijne Peerlinck, Christopher J. Penkett, David J. Perry, Catherine Roughley, Ilenia Simeoni, Kathleen Stirrups, Daniel P. Hart, R. Campbell Tait, Andrew D. Mumford, NIHR BioResource, Michael A. Laffan, Kathleen Freson, Willem H. Ouwehand, Shinji Kunishima, Ernest Turro

Check for updates

Blood (2017) 129 (4): 520–524.



TUBB1 p.Gly109Glu

PLATELETS AND THROMBOPOIESIS | DECEMBER 16, 2021

Expanding the genetic spectrum of *TUBB1*-related thrombocytopenia


Verónica Palma-Barqueros, Loredana Bury, Shinji Kunishima, María Luisa Lozano, Agustín Rodríguez-Alen, Nuria Revilla, Natalia Bohdan, José Padilla, María P. Fernández-Pérez, María Eugenia de la Morena-Barrio, Ana Marín-Quiles, Rocío Benito, María F. López-Fernández, Shally Marcellini, Ana Zamora-Cánovas, Vicente Vicente, Constantino Martínez, Paolo Gresele, José M. Bastida, José Rivera on behalf of the Inherited Platelet Disorders Project, Grupo Español de Alteraciones Plaquetarias Congénitas (GEAPC), Spanish Society of Thrombosis and Haemostasis (SETH)

Check for updates

Blood Adv (2021) 5 (24): 5453–5467.

for rare or low prevalence complex diseases

Network
Hematological
Diseases (ERN EuroBloodNet)



Detection of a missed diagnosis



- ✓ Healthy parents
- ✓ Child (boy) with platelet count of 8K, died after intracranial bleed
- ✓ 2nd child (girl) with platelet count of 12K, easy bruising
- ✓ CAMT screening negative !
- ✓ next WES

Received: 13 August 2022 | Accepted: 15 September 2022


DOI: 10.1111/bjh.18481



LETTER TO THE EDITOR

Maternal gonosomal mosaicism in rare autosomal dominant *SLFN14*-related thrombocytopenia

Precision diagnosis of IT can influence management



Transcriptional regulation

ANKRD26
RUNX1
ETV6
GATA1
GFI1B

Leukaemia risk
Dyserythropoiesis/ anaemia

Cytoskeleton


ACTN1 Benign
TUBB1
MYH9 Genotype/phenotype hearing loss/ kidney failure
DIAPH1 Hearing loss/ TPO mimetics

WAS Infections/transplant

TPO signaling

MPL Pancytopenia /transplant
THPO Pancytopenia /TPO mimetics

When do we use the multi-gene panel test in the diagnostic algorithm?



Gresele et al. *Inherited Platelet Function Disorders: Algorithms for Phenotypic and Genetic Investigation. Seminars in Thrombosis and Hemostasis*. 2016




for rare or low prevalence complex diseases

Network
Hematological
Diseases (ERN EuroBloodNet)



Other genetic studies for IT (outside diagnostic environment)

Clinical relevance of rare variants & polygenic scores for IT?



The effects of pathogenic variants for inherited hemostasis disorders in 140,214 UK Biobank participants

- Effect of Rare and Common variants
- Common variants are polygenic scores (PGS)



Network
for rare or low prevalence
complex diseases

Network
Hematological
Diseases (ERN EuroBloodNet)

Stefanucci L et al, Blood 2023




Diagnostic rate

+/- 55%



Plus 10%

?



Multi Gene Panel Test

Whole Genome Sequencing

Blood transcriptomics


















Other omics?

1. Clinic

2. Research

Gene discovery using WGS




	Bleeding, thrombotic and Platelet Disorders	BPD		Multiple Primary Malignant Tumours	MPMT
	Cerebral Small Vessel Disease	CSVD		Neurological and Developmental Disorders	NDD
	Ehler-Danlos Syndromes	EDS		Neuropathic Pain Disorders	NPD
	Rare Diseases Pilot-II	GEL		Pulmonary Arterial Hypertension	PAH
	Hypertrophic Cardiomyopathy	HCM		Primary Immune Disorders	PID
	Intrahepatic Cholestasis of Pregnancy	ICP		Primary Membranoproliferative Glomerulonephritis	PMG
	Inherited Retinal Disorders	IRD		Stem cell and Myeloid Disorders	SMD
	Leber Hereditary Optic Neuropathy	LHON		Steroid Resistant Nephrotic Syndrome	SRNS
		UK Biobank – Extreme Red Cell Traits		UKBio	


- **57 NHS Hospitals and 26 non-UK Hospitals**

(Bleeding & Platelet Disorders 1916 patients)

- **13,037 index patients**



2011-2020: 18 new genes for bleeding & platelet disorders




UZLeuven (543 patients):
Only 10% diagnostic rate

Albers *et al*, Nat Genetics 2011; Albers *et al*, Nat Genetics 2012; Cvejic *et al*, Nat Genetics 2013; Chen *et al*, Science 2014; Westbury *et al*, Genome Medicine 2015; Green *et al*, AJHG 2016; Stritt *et al*, Nat Comm 2016; Turro *et al*, Science Transl Med 2016; Stritt *et al*, Blood 2016; Simeoni *et al*, Blood 2016; Lentaingne *et al*, Blood 2016; Poggi *et al*, Haematologica 2016; Bariana *et al*, BJH 2017; Siva-palaratnam *et al*, Blood 2017; Pleines *et al*, JCI 2017; Greene *et al*, AJHG 2017; Westbury *et al*, Blood 2017; Sivapalaratnam *et al*, BJH 2017; Morren *et al*, Orphanet 2017; Freson *et al*, JTH 2017; Sowerby *et al*, JCI 2017; Mayer *et al*, Blood 2018; Revel-Vilk *et al*, Blood 2018; Berrou *et al*, Blood 2018; Hofman *et al*, Blood 2018; Bariana *et al*, Haematologica 2018; Westbury *et al*, Blood Adv 2018; Lentaingne *et al*, Blood 2019; Buyse *et al*, HMG 2021


Gene discovery using Whole Genome Sequencing




DIAPH1-related thrombocytopenia + deafness



IKZF5-related thrombocytopenia




SRC-related syndromic thrombocytopenia



Large pedigrees

Turro et al, 2016, Science Translational Medicine

GATA1/HDAC6-related thrombocytopenia + Autism




Unique DELETION

Turro et al, 2020, Nature


Unrelated patients with same genotype-phenotype
BeviMed (Ernest Turro, Daniel Greene- Mount Sinai NY)

Blood cell RNAsequencing


20 controls
9 Thrombocytopenia patients
18 platelet functional disorders




PLATELETS



CD4+ T cells



monocytes



Neutrophils

Raresevoir (Variant filtering) & Chromoscope (Variant display)



A002707

kathleen.freson@kuleuven.be / IP: 193.80.92.187 (proxy for 134.58.253.56)

sample: A002707, gnomad: absent, cadd_thresh: 10, filter: moderate, splice_ai: null, biallelic: false


[Main page](#) [DB info](#) [Logout](#)

Show sample data

[Help](#) [Download](#) Highlight domain: ☐ None ☐ Retain highlighted SpliceAI threshold for intronic: 0

Include variants by consequence: ☒ no gene consequence ☒ coding_sequence_variant ☒ exonic_splice_region_variant ☒ five_prime_UTR_variant ☒ frameshift_variant ☒ inframe_deletion ☒ intron_variant
☒ missense_variant ☒ splice_donor_variant

Gene	CHR	POS	REF	ALT	Samples	Consequence	HGVS	CADD	gnomAD freq	SpliceAI	HGMD
OR10J1	1	159410244	C	G	A002707	missense_variant	Ile232Met	22.30	absent	0.01	
KCNJ10	1	160011584	G	A	A002707	missense_variant	Pro247Ser	26.30	absent	0.04	
RXRG	1	165378877	G	T	A002707	missense_variant	Gln322Lys	19.48	absent	0.16	
ZNF281	1	200377438	T	C	A002707	missense_variant	Arg466Gly	16.53	absent	0.00	
ENSG00000268146	1	244228363	C	T	A002707, M006451	missense_variant	Arg150Cys	10.72	absent	0.00	
C2orf80	2	209045956	C	T	A002707	missense_variant	Ala94Thr	25.90	absent	0.11	
ABHD14B ABHD14A-ACY1 ACY1 ABHD14A	3	52009186	T	C	A002707	missense_variant & five_prime_UTR_variant & intron_variant	Leu12Pro,Leu12Pro,Leu12Pro,Leu12Pro,Leu12Pro,Leu12Pro,Leu12Pro,Leu12Pro	22.40	absent	0.00	
APBB2	4	41016334	G	A	A010817, A002707, A002720	missense_variant	Thr34Ile	23.70	absent	0.00	
KDM3B	5	137721856	T	G	A002707	missense_variant	Val309Gly	19.26	absent	0.22	
CDHR2	5	176004545	T	C	A002707	missense_variant	Met447Thr	22.70	absent	0.01	
NSD1	5	176636935	A	G	A002707	missense_variant		21.40	absent	0.00	
DEK	6	18264081	CTC[22]TCG	C	A002707	inframe_deletion	Asp37_Glu45del		absent	0.19	
NR2E1	6	108497902	A	G	A002707	missense_variant	Glu189Gly	23.30	absent	0.00	
PNPLA8	7	108137930	T	C	A002707	missense_variant	Thr484Ala	26.10	absent	0.01	
CPA6	8	68397000	G	A	A002707	missense_variant	Pro221Ser	18.55	absent	0.12	
ADAMTSL2	9	136435570	G	A	G003517, K002589, S013694, T011086, A002707, W000325, W000328, B012575, U007109, C006877,	missense_variant	Glu954Lys	22.70	absent	0.00	



Key messages for use of an NGS panel test for diagnostics



- ✓ A (virtual) panel test is fast (TAT 4-6 months) and cheap
- ✓ It detects unexpected phenotype-genotype associations (including unsolicited findings)
- ✓ Panel test is typically ordered by specialist with knowledge of the complexity of such test and its inclusion/exclusion criteria. Patients should be aware of what this test means (opt-out for RUNX1, ETV6, ANKRD26 and consenting).
- ✓ Sufficient phenotype information should be provide to allow variant classification
- ✓ Variants of Unknown clinical Significance (VUS- need further research (improved variant databases) before they can be used in the clinic

Acknowledgements



CMVB

UZLeuven & CMVB


Veerle Labarque
Chris Van Geet

Kathelijne Peerlinck
Thomas Vanassche
Peter Verhamme

Chantal Thys
Christine Van Laer
Andreas Verstraete

Human Genetics, UZLeuven

Anniek Corverleyn
Sarissa Baert
Karen Willekens



All Belgian Clinical Centers for thrombosis & Hemostasis